Methods and Compositions for Identifying and Using Vif Inhibitors to Restore Antiviral APOBEC3G Activity

Background

Human Immunodeficiency Virus type 1 (HIV-1) remains a significant global health challenge, with millions of individuals affected worldwide. The virus’s ability to evade the host immune system and develop resistance to existing antiretroviral therapies necessitates ongoing research into novel therapeutic strategies. One area of intense focus is the interaction between HIV-1 and host restriction factors, such as the APOBEC3G (A3G) cytidine deaminase. A3G is a natural antiviral protein that can induce lethal hypermutations in the viral genome, thereby inhibiting HIV replication. However, HIV-1 has evolved mechanisms to counteract this defense, most notably through the viral infectivity factor (Vif) protein, which neutralizes A3G’s antiviral activity. This interplay highlights the need for innovative approaches that can restore or enhance the host’s innate ability to combat HIV-1.

Current antiretroviral therapies primarily target viral enzymes such as reverse transcriptase, protease, and integrase, but these approaches are limited by the rapid emergence of drug-resistant viral strains and the inability to eradicate latent reservoirs. Moreover, existing treatments do not address the specific mechanism by which Vif suppresses A3G, leaving a critical aspect of the host-virus interaction unexploited. Efforts to inhibit Vif have been hampered by the lack of robust, high-throughput screening methods to identify compounds that can effectively disrupt Vif’s interaction with A3G and restore its cytidine deaminase activity. As a result, there is a pressing need for new strategies that can directly target this pathway, offering the potential for more durable and broadly effective HIV therapies.

Technology

This technology provides a comprehensive platform for identifying and developing compounds that inhibit the HIV-1 viral infectivity factor (Vif), a key protein that allows HIV to evade the host immune response. The approach centers on a biochemical assay that combines the APOBEC3G (A3G) cytidine deaminase, Vif, and a specific oligonucleotide substrate. By introducing candidate compounds to this mixture and measuring the conversion of a CCC sequence to a CCU sequence via quantitative PCR, researchers can determine whether a compound effectively blocks Vif’s suppression of A3G activity. The technology also includes a portfolio of Vif-inhibiting compounds—such as derivatives of cefixime, redoxal, genistein, natamycin, aurintricarboxylic acid, and quinobene—which are formulated into pharmaceutical compositions for the treatment or prevention of HIV and potentially other viral infections.

This solution is differentiated by its targeted mechanism of action, which focuses on restoring the natural antiviral activity of A3G rather than directly attacking the virus itself. By inhibiting Vif, these compounds enable A3G to induce lethal G to A hypermutations in the viral genome, thereby reducing viral infectivity and replication. The use of a quantitative, high-throughput assay allows for efficient screening and validation of potential inhibitors, accelerating drug discovery. Furthermore, the identification of specific, repurposable compounds with established safety profiles enhances the translational potential of this approach, offering a novel therapeutic strategy that complements existing antiretroviral therapies and addresses the challenge of viral resistance.

Benefits

• Restores APOBEC3G cytidine deaminase activity by inhibiting HIV-1 Vif function
• Reduces HIV viral infectivity and replication through enhanced viral genome hypermutation
• Enables identification of effective Vif inhibitors using a quantitative and specific assay method
• Provides pharmaceutical compositions with multiple candidate compounds for HIV treatment or prevention
• Targets a novel mechanism in HIV replication, potentially overcoming resistance to existing therapies

Applications

• HIV therapeutic drug development
• High-throughput antiviral compound screening
• Personalized HIV treatment formulations
• Diagnostic assays for Vif inhibitors

Additional info

This collection details methods and compounds for identifying agents that inhibit HIV-1 Vif’s suppression of APOBEC3G cytidine deaminase activity. The core identification method quantifies oligonucleotide CCC to CCU conversion. Identified compounds, including cefixime derivatives, restore A3G function, inhibiting viral infectivity and replication. These are formulated into pharmaceutical compositions for treating or preventing viral infections.